Rare diseases do not receive enough attention for the impact they have on patients and their families. This is what AlphaRose’s founder and CEO Casey McPherson learned after his daughter was diagnosed with a rare condition. In a conversation with host Ari Berman, McPherson shares how he switched from music to founding his own pharmaceutical company, what technologies AlphaRose is developing, and how his company is creating environments that allow innovation and iteration. He also shares his t...
All content for Trends from the Trenches is the property of Bio-IT World and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Rare diseases do not receive enough attention for the impact they have on patients and their families. This is what AlphaRose’s founder and CEO Casey McPherson learned after his daughter was diagnosed with a rare condition. In a conversation with host Ari Berman, McPherson shares how he switched from music to founding his own pharmaceutical company, what technologies AlphaRose is developing, and how his company is creating environments that allow innovation and iteration. He also shares his t...
Episode: 27 - Law to Biotech: Joseph La Barge on Starting a Company and the Future of Gene Therapy
Trends from the Trenches
25 minutes
1 year ago
Episode: 27 - Law to Biotech: Joseph La Barge on Starting a Company and the Future of Gene Therapy
In this month’s episode of Trends from the Trenches, host Stan Gloss speaks with Joseph La Barge. La Barge trained as an attorney but has spent most of his career building biotech businesses and securing funding. He shepherded Spark Therapeutics through its acquisition by Roche and has since joined Apertura Gene Therapy as CEO. He and Stan talk about the entrepreneurship journey, gene expression and capsid engineering, and Apertura’s future goals and projects. Links from this episode: &...
Trends from the Trenches
Rare diseases do not receive enough attention for the impact they have on patients and their families. This is what AlphaRose’s founder and CEO Casey McPherson learned after his daughter was diagnosed with a rare condition. In a conversation with host Ari Berman, McPherson shares how he switched from music to founding his own pharmaceutical company, what technologies AlphaRose is developing, and how his company is creating environments that allow innovation and iteration. He also shares his t...
